Link Plus Forms Subsidiary to Develop MIPs-Based Solutions for Detection and Filtering of Viruses for Public Health

COLUMBIA, MD, Jan 22 (MARKET WIRE) --
Link Plus Corporation announced today that it has formed a subsidiary
called Link Plus BioTech, Inc. to focus on public health related applications of
Molecularly Imprinted Polymers (MIPs) technology for the specific detection,
binding, and separation of viruses. The creation of Link Plus BioTech results
from
the exclusive license agreement with the University of Maryland for the
technology. The parent company, Link Plus Corporation, will remain focused on
the homeland security applications of this latest MIPs technology.

Robert L. Jones, Jr. was named the Chairman and CEO of Link Plus BioTech.
Dr.
Peter Kofinas, Professor, Associate Chair, and Director of Graduate Studies in
University of Maryland's Fischell Department of Bioengineering, was named as
Link Plus
BioTech's Chief Technology Officer.

Kofinas is widely regarded as the leading research scientist in the field of
applying MIPs technology to biological threats. He and his team at the
University have successfully detected viruses using the MIPs technology
andsensor systems that have the ability to be commercially deployed. Future
research by Link Plus BioTech will expand on the breadth of viruses which can
be detected and extend the technology to a myriad of antibiotic-resistant
bacteria, including MRSA.

"Dr. Kofinas and his colleagues at the University of Maryland pioneered
theuse of MIPs technology in biotech, and we are happy to bring Peter on
boardas we launch Link Plus BioTech," said Robert L. Jones, Jr., CEO of Link
Plus
BioTech. "The creation of Link Plus BioTech allows us to establish a sharp
focus on the application of MIPs for public health related needs. For
example, a dialysis system can be developed consisting of custom synthesized
molecularly imprinted polymers packaged into plastic discs (cartridges) that
are compatible with commercially available blood screening dialysis and
hemodialysis devices. This will enable hospitals, clinics, and other healthcare
organizations to turn existing dialysis, hemodialysis, or blood analysis systems
into virus removal systems capable of lowering the viral load (concentration of
virus) in patients with HIV, Hepatitis B, Hepatitis C, or other blood-borne
viruses by the direct removal of viruses from the bloodstream. While this is not
a cure, it should aid in treatment of these diseases. In another example, MIPs
technology could lower the cost of vaccine production. When a vaccine is
produced, the viral particles needed to make the vaccine must be separated
from the biomass in which they reside. Currently, this is an expensive, time
consuming, and difficult process. This could be accomplished inexpensively by
filtering the biomass through a MIPs hydrogel, which would trap only what
is needed to make the vaccine while letting the debris pass through."

Dr. Kofinas commented that "Mr. Jones has the business expertise and I
havethe technical knowledge to convert the technology into a marketable
product." Dr.
Kofinas co-invented and developed the technology with Ph.D student Daniel
Janiak at the University of Maryland.

About Link Plus BioTech, Inc.

The detection and separation of viruses and virus-like particles
(non-infectious
virus analogs) from medically relevant media represents an enormous
challenge to the fields of medicine, healthcare, and biotechnology. The goal
of Link Plus BioTech, Inc. is to provide novel, low-cost, high-throughput
devices for the separation of viruses and virus-like particles. This will be
achieved through extensive research and development efforts with the ultimate
goal of continuously developing products and devices to aid in the management,
treatment, and diagnosis of viruses.

The exclusive licenses and relationships with the University of Maryland and
The
Johns Hopkins University for MIPs technology that are held by the parent
company Link Plus Corporation, provides Link Plus BioTech, Inc. and its
parent with unique access to the research and development capabilities of two
outstanding research institutions.

This news release includes "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements involve risks and uncertainties, which may cause results to
differ materially from those set forth in the statements. The forward-looking
statements may include statements regarding product development, product
potential or financial performance. No forward-looking statement can be
guaranteed, and
actual results may differ materially from those projected.

Link Plus Corporation and Link Plus BioTech, Inc. headquarters are located
in
Columbia, MD. Further information is available at http://www.linkplus.com
(410) 953-7177.

Robert L. Jones, Jr.
Chairman and CEO
Link Plus BioTech, Inc.
(410)-953-7177
rjones@linkplus.com

Copyright 2008, Market Wire, All rights reserved.

-0-